A Scoping Review of Scientific Evidence (2024)

Abstract

Over the last few decades, health evidence has been building for hibiscus tea (Hibiscus sabdariffa L. Malvaceae). Previous reviews show promise in relation to reducing cardiovascular risk factors, hypertension and hyperlipidaemia, but broader health perspectives have not been widely considered. Therefore, a scoping review was undertaken to examine the overall health effects of hibiscus tea. A PubMed search was undertaken for metaanalysis (MA) and systematic review papers, human randomised controlled trials (RCT) and laboratory publications investigating inter-relationships between hibiscus tea and health. Twenty-two publications were identified (four systematic/MA papers, nine human RCT controlled trials and nine laboratory publications).Strongest evidence exists in relation to cardiovascular disease, suggesting that drinking 2-3 cups daily (each ≈ 240-250 mL) may improve blood pressure and potentially serve as a preventative or adjunctive therapy against such conditions. Emerging evidence exists for favourable effects on lipid profiles, insulin resistance, oxidative stress and inflammation. Further research using larger and longer human studies is warranted.

Keywords

Hibiscus tea; Health; Antioxidants; Polyphenolic compounds; Cardiovascular disease; Blood Pressure

Hibiscus tea is usually derived from the dried calyces of the tropical plant Hibiscus sabdariffa L. (HSL) which belongs to the mallow family (Malvaceae) [1]. It is thought to be a native of West Africa, but is commonly cultivated across the tropics and subtropics including in China, Egypt, Mexico, Thailand and the West Indies [2]. HSL is sometimes referred to in English as ‘roselle’ or ‘red sorrel’ and in Arabic as ‘karkade’ [3]. This naming is attributed to its colouring with the roselle calyx being a bright red colour and abundant in anthocyanins [4]. It is the calyces (outer parts of the flower) that are most commonly used worldwide, to make hot and cold infusions [3]. HSL is also rich in organic acids and thus is also referred to as ‘sour tea’ due to these providing a distinctive tart taste [5].

Hibiscus tea is becoming increasingly popular which largely appears to be attributed to its bioactive properties, which could benefit public health [6,7]. From a historical perspective HSL has been used in folklore and traditional medicines [8,9]. Its rich phytonutrient profile may be responsible for such reported health effects [1]. For example, the phenolic acid protocatechuic acid, organic acids (hydroxycitric acid and hibiscus acid) and anthocyanins (delphinidin-3-sambubioside and cyanidin-3-sambubioside) have been listed as important bioactive components within HSL [10]. A compositional analysis of Hibiscus calyces found these to be rich in lutein, chlorogenic acids and delphinidin 3-sambubioside [11]. HSL extracts have additionally been found to have antioxidant and antimicrobial properties [7].

A growing body of evidence suggests that herbal teas, including HSL could benefit aspects of preventative and clinical health [8]. For example, one MA [5] of five RCT comprised of 390 participants found that HSL had significant effects lowering both systolic and diastolic blood pressure. HSL extracts have also been found to have anti-diabetic, anti-hypertensive, nephro- and hepato-protective effects as well as potential benefits on lipid metabolism and renaldiuretic effects [10]. These actions have been ascribed to HSL extracts having a notable antioxidant profile, vasorelaxant effects and ability to inhibit α-glucosidase, α-amylase, angiotensin-converting enzymes and modulate calcium channels [10]. Other work has reported that HSL could also have potential anti-obesity actions [12,13]. A systematic review of ten studies concluded that HSL may have a role in the treatment of mild to moderate hypertension, although ongoing research is warranted [14].

Taking the growing evidence-base on board, the present scoping review aims to collate evidence from systematic reviews, MA papers, human trials and laboratory studies, investigating inter-relationships between hibiscus tea consumption and health.

Study design

Scoping reviews are useful for collating evidence on a topic-they are a form of knowledge synthesis and useful for answering broader questions, including what is known about a concept [15].

For the screening of human trials the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach was used (Figure 1) [16]. Alongside this, the recently published PRISMA Extension for Scoping Reviews (ScR) checklist developed by a 26-member expert panel was also applied. [16] The quality of human trials was further determined using the validated Jadad criterion [17].

Figure 1: PRISMA approach used to identify studies.

Inclusion/Exclusion criteria

The present scoping review analysed associations between hibiscus tea and markers of health. Included papers were published in Englishlanguage in peer-reviewed journals. Human trials were screened and used hibiscus delivered as teas, infusions or aqueous extracts (specifying the amount consumed) rather than concentrated extracts or supplements. Trials were limited to RCTs using the PubMed search restriction tab. RCTs are regarded as the ‘gold-standard’ for identifying causal relationships as they largely eliminate bias typically associated with other study designs [18].

Multi-interventions using combinations of tea infusions, medications, tea supplements, condensed extracts or other interventions that could potentially confound results were excluded when screening human studies. Interventions, however, where different tea forms were randomly allocated to separate groups of participants were included. No time restrictions were applied for the systematic, MA review or RCT search. A restriction of ten years was applied to the laboratory studies.

Search strategy & data charting

The search for relevant studies was conducted using the PubMed database. For the identification of publications, the search terms “Hibiscus tea” or “Hibiscus sabdariffa tea” or “roselle tea” or “sour tea” were used and acknowledged as text words [tw] within the PubMed search strategy. Further to this, a manual search for publications was undertaken by screening the references listed in key studies. The search focused on gathering evidence from: (1) Prior systematic review and MA papers, (2) Human trials and (3) Laboratory publications (studies and reviews). Search restrictions were customised and limited to: Systematic reviews, MA papers, human RCTs and laboratory publications.

Studies were screened using the listed inclusion/exclusion criteria and identified by the two contributing authors. Studies were initially screened using their title. They were then further verified using the abstract. The procedure of identification, screening, evaluation of eligibility and inclusion is illustrated in Figure 1.

Data charted from the human trials included the following: General details of the study, participants, study design, tea intervention (type and dosage), health outcome(s) and main study findings with any reported significant p-values. For laboratory publications data relating to the study and its design (laboratory model) were extrapolated, Hibiscus intervention/focus and health outcomes were extracted along with the main findings.

Results

The search for articles identified 31 publications initially (seven MA papers, eight RCTs from PubMed, three RCTs from literature sources and 13 laboratory papers). Of these, three systematic/MA papers and four laboratory publications were irrelevant and two trials used supplements or medications. Subsequently 22 papers were eligible for inclusion within the review-four systematic/MA papers, nine human RCTs and nine laboratory studies (Figure 1).

Most of the articles focused on aspects of cardiovascular wellbeing (Table 1). Three concentrated on hypertension or blood pressure [5,19,20] and two serum lipid levels [21,22]. Two MA studies found that both sour tea and HSL significantly reduced systolic and diastolic blood pressure [5,19]. Significant reductions in plasma glucose levels were also observed in an analysis conducted by Najafpour Boushehri S, et al. (2020) [19]. In earlier reviews, findings were less conclusive. Aziz Z, et al. (2013) [21] collated evidence from six RCTs involving 474 participants and found no associations between HSL ingestion and total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol nor triglyceride levels. Hajifaraji M, et al. (2018) [22] observed significant reductions in mean total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol levels compared to baseline values after participants with genetic (polygenic) dyslipidaemia ingested two cups of sour tea daily. Wahabi HA, et al. (2010) [20] collated data from four trials comprised of 390 patients finding that HSL did not appear to be an effective treatment for primary hypertension, although these trials were regarded to be poor quality.

Table 1: Hibiscus tea and health: Evidence from systematic reviews and meta-analysis papers.
*DBP- Diastolic Blood Pressure; HSL- Hibiscus sabdariffa L.; RCTs- Randomised Controlled Trials; SBP- Systolic Blood Pressure

Regarding human RCTs five focused on blood pressure or hypertension (Table 2) [23-27]. Four reported on lipid levels and profiles [23,28-30]. Some RCTs investigated other health outcomes including oxidative stress, [28] insulin resistance, [23,28] and inflammation [23]. Abubakar SM, et al. (2019) [23] researched vascular function and a cardiovascular disease (CVD) risk calculation was undertaken. All the RCTs observed notable improvements in health outcomes, which included improved postprandial vascular function [23], triglyceride levels [29-30], high-density lipoprotein cholesterol levels [28,30], insulin resistance [23,28] and blood pressure profile [24-27].

Table 2: Hibiscus tea & health: Evidence from human trials.
*BP- Blood Pressure; CVD- Cardiovascular disease; DB- Double-blind; DBP- Diastolic Blood Pressure; HDL-C- High-Density Lipoprotein Cholesterol; HSLHibiscus sabdariffa Linne; HSC- Hibiscus sabdariffa calyces; LDL-C- Low-Density Lipoprotein Cholesterol; RCT- Randomised Controlled Trial; SB- Singleblind; SBP- Systolic Blood Pressure; ST- sour tea; STE- Sour Tea Extract; TG- Triglyceride.

Of the interventions delivered infusions were generally given one to three times daily. Abubakar SM, et al. (2019) [23] steeped 30g (an average of 15 hibiscus tea bags) of Hibiscus sabdariffa calyces in 1 litre of low nitrate water for 10 min. Each volunteer was then served an equivalent extract of 7.5 g Hibiscus sabdariffa calyces (about 3-4 hibiscus tea bags) in 250 mL Buxton water once daily. In four other studies 240 mL servings were delivered two or three times daily with this appearing to benefit systolic and diastolic blood pressure and triglyceride levels [25,26,29,30]. Some studies administered the tea interventions with a date or sugar cube to aid compliance in case the tea flavour was disliked [26,28].

As shown in Table 3 seven studies scored 3 or more after applying the Jadad criteria indicating that they were of moderate to high quality. One study [29] did not mention randomisation methods nor specify whether blinding was undertaken so was graded as lower quality (a score of 2). The three studies that were ‘moderate quality’ received lower scores because blinding methods were not clearly specified [24,27,28].

Table 3: Jadad criterion used to assess quality of RCTs.
Total quality assessment score for which scores range between 1 and 5: with 1 being the lowest quality and 5 being the highest quality. 3=above average quality.

Nine laboratory publications were identified; the majority which were murine models (Table 4). Various HSL interventions were used. Five papers reported that they used aqueous extracts, infusions or drinks [31-35]. Earlier work by Hopkins AL, et al. (2013) [36] purported that HSL reduced cholesterol, low-density lipoprotein cholesterol and triglycerides in most diabetic, hyperlipidaemic and normolipidemic laboratory models. Similarly, Lin HH, et al. (2011) [37] evaluated laboratory models using various HSL forms finding that these appeared to benefit atherosclerosis, cancer, diabetes, liver disease and metabolic syndromes.

Table 4: Hibiscus Tea and Health: Evidence from Laboratory Publications.
*CKD- Chronic Kidney Disease; HDL-C- High-Density Lipoprotein Cholesterol; HPAIVs- Highly Pathogenic Avian Influenza Viruses; HSL- Hibiscus sabdariffa L.; LPAIVs- Low Pathogenic AIVs; LDL-C- Low-Density Lipoprotein Cholesterol; LPS- Lipopolysaccharide; MI- Myocardial infarction; NF-kB- Nuclear FactorκB; OB- Obese; TGs- Triglyceride.

Two laboratory models [31,33] one fed a high fat diet observed improvements in cardiac function, which was most likely mediated through antioxidant activities. Lee YS, et al. (2018) [38] used a synergistic intervention which included hibiscus flower extracts and found that these reduced obesity in mice fed a high-fat diet. Some work showed that HSL calyces or a roselle drink reduced hepatic and renal inflammation, respectively, possibly by down regulating biochemical components of inflammatory pathways [34,39]. One study [32] reported renal benefits amongst rodents with induced chronic kidney disease effects that were ameliorated in a dose-dependent manner. Surprisingly one study by Mahmoud YI (2012) [35] observed that aqueous extracts from dried HS calyx inversely influenced male murine reproductive fertility but these effects have not since been replicated.

Beyond the span of this scoping review HSL extract has also been found to alter parameters associated with the development of obesity, including cholesterol metabolism, lipid accumulation, adipocyte differentiation and adipogenesis and its inhibitory effects on pancreatic lipase [13]. Some research [40,41] using a combination of HSL polyphenolic extracts and Lippia citrodora Paláu (syn Aloysia citrodora) Verbenaceae observed improved, blood pressure and heart rate parameters amongst obese adults with observed increases in anorexigenic and reductions in orexigenic hormones. Moreover, a multicentric pilot clinical study [42] of 38 adults with blood pressure above 140/90mmHg showed that HSL (10-20 g of HSL per 0.5 litres of tea daily) was helpful in treating uncontrolled hypertension and well tolerated. Work conducted with soccer players also demonstrated that 450 mg/d sour tea extracts after 6-weeks had beneficial effects on oxidative stress [43].

The scoping review of scientific evidence found the strongest evidence-base for HSL and cardiovascular wellbeing. Three synthetic reviews, which included MA research, reported benefits for blood pressure and hypertension [5,19,20]. Five underpinning human RCTs also consistently observed improvements in blood pressure, particularly systolic blood pressure [23,25-28]. Evidence for serum lipids was less certain. For example, Hajifaraji M, et al. (2018) [22] concluded that sour tea could impact beneficially and significantly on subjects with polygenic dyslipidaemia, which could partly be attributed to its anthocyanin content and the genetic status of subjects. In contrast, earlier work undertaken by Aziz Z, et al. (2013) [21] found that evidence from the six RCTs analysed could not identify definite links between HSL and reduced serum lipids. Authors, however, reported that studies had small sample sizes and were underpowered which could have been attributed to the lack of findings.

It should also be considered that most studies recruited participants with CVD risk factors, hypercholesterolemia, hypertension or type 2 diabetes at baseline, thus were not healthy. This indicates that hibiscus tea consumption could be a useful adjunctive therapy from a protective health stance, particularly amongst individuals at risk of cardiovascular disease. Most human studies provided two-three servings of sour or brewed hibiscus tea daily with a serving typically being 240-250 mL [24-26,28-30]. Thus it would be reasonable to suggest that hibiscus tea drinking could be adopted as a dietary strategy to enhance individuals with elevated blood pressure or CVD risk. It has previously been reported that HSL extracts have a low degree toxicity and excellent safety tolerability [10,36] although some caution may be required if planning to conceive or pregnant [35,44].

In terms of potential mechanisms, it is well documented that the polyphenol profile of hibiscus tea could play a role in its health benefits and potential modern therapeutic uses [1]. Regarding cardiovascular benefits it has been postulated that the antioxidant effects of HSL induced by its anthocyanin profile could inhibit low-density lipoprotein oxidation, subsequently impeding atherosclerosis [36]. Other theories include that anthocyanins reduce low-density lipoprotein oxidation and inhibit adipogenesis via the regulation of transcription factors and adipogenic signalling pathways, which modulate the gene expression of certain microRNAs [45]. Recent work with type 1 diabetic rats has further shown that HSL renews pancreatic β-cells [46]. Laboratory publications suggest potential cardiac [31,35] and anti-inflammatory actions [34,39]. There was emerging evidence from human trials that hibiscus tea could have beneficial effects on insulin resistance [23,28] and levels of oxidative stress [28]. Ongoing human RCTs are now needed to focus on these aspects as primary research outcomes.

Other work has focused on how HSL could affect parameters of nutritional status. Research conducted on patients with vitamin B₁₂ deficiency and neurological symptoms who were given a combination of hydroxocobalamin and HSL found that vitamins injections were no longer required to replete B₁₂ status [47]. Extended research by this team of scientists using laboratory models confirmed that the bioavailability of intestinal hydroxocobalamin increased when synergistically used with HSL [47]. Ongoing work is now needed to replicate findings and further determine whether hibiscus tea could improve the bioavailability of nutrients, such as vitamin B12-findings that could potentially be of benefit to vegetarian or vegan populations. Elsewhere it has been observed that the iron and organic acid profile of HSL could potentially improve hematopoietic (iron status) parameters but larger human studies are needed [48,49].

With respect to limitations it should be considered that studies varied in terms of duration, forms of interventions and comparators used. Future studies should continue to use interventions that ultimately translate into public health guidance. Undoubtedly, more welldesigned RCTs are needed using ‘phytochemically characterised’ preparations, which would aid comparative analyses between studies [10,50]. It must be indicated that future trials should better include and describe blinding methods to improve their quality. Clear randomisation approaches should also be adopted and outlined in publications. Certain populations such as pregnant mothers and those with kidney problems may be cautious to avoid excessive consumption of hibiscus infusions due to these being a source of aluminium which could accumulate in the body [51]. More research is also needed to better understand the toxicology of hibiscus as the ingestion of condensed HSL extracts would be somewhat different to that of infusions-excessive doses of HSL calyx doses, for example, over long durations have been found to have deleterious effects on testes of rats [3].

The present scoping review shows that hibiscus tea ingestion could benefit cardiovascular wellbeing. Emerging research also reveals potential benefits in terms of its ability to favourably modulate lipid profiles, inflammation, oxidative stress and insulin resistance. From a habitual perspective hibiscus tea could be consumed for its favourable phytonutrient profile and potential cardiovascular benefits. More extensive research is now warranted in the form of larger and longer human trials with clearly defined interventions.

The views expressed are those of the authors alone and personnel from the UK TEA & INFUSIONS ASSOCIATION (UKTIA) had no role in writing this review

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgements

The authors received funding provided by the Tea Advisory Panel which is supported by an unrestricted educational grant from the UK TEA & INFUSIONS ASSOCIATION (UKTIA), the trade association for the UK tea industry. UKTIA plays no role in producing the outputs of the panel. Independent panel members include nutritionists, biochemists, dietitians, dentist and doctors. See www. teaadvisorypanel.com

References

1. Riaz G, Chopra R (2018) A Review on Phytochemistry and TherapeuticUses of Hibiscus sabdariffa L. Biomed Pharmacother 102: 575-586. [Ref.]
2. El-Saidy SM, Ismail IA, EL-Zoghbi M (1992) A study on Roselleextraction as a beverage or as a source for anthocyanins. Zagazig JAgric Res 19: 831-839. [Ref.]
3. Ali BH, Al Wabel N, Blunden G (2005) Phytochemical, Pharmacologicaland Toxicological Aspects of Hibiscus sabdariffa L.: A Review.Phytother Res 19: 369-375. [Ref.]
4. Wu HY, Yang KM, Chiang PY (2018) Roselle Anthocyanins: AntioxidantProperties and Stability to Heat and pH. Molecules 23: 1357. [Ref.]
5. Serban C, Sahebkar A, Ursoniu S, Andrica F, Banach M (2015) Effectof Sour Tea (Hibiscus sabdariffa L.) on Arterial Hypertension: ASystematic Review and Meta-Analysis of Randomized ControlledTrials. J Hypertens 33: 1119-1127. [Ref.]
6. Hassan ST, Berchova K, Šudomová M (2016) Antimicrobial,Antiparasitic and Anticancer Properties of Hibiscus sabdariffa (L.)and Its Phytochemicals: In Vitro and in Vivo Studies. Ceska Slov Farm65: 10-14. [Ref.]
7. Jabeur I, Pereira E, Barros L, Calhelha RC, Soković M, et al. (2017)Hibiscus sabdariffa L. As a Source of Nutrients, Bioactive Compoundsand Colouring Agents. Food Res Int 100: 717-723. [Ref.]
8. Wright CI, Van-Buren L, Kroner CI, Koning MMG (2007) HerbalMedicines as Diuretics: A Review of the Scientific Evidence. JEthnopharmacol 114: 1-31. [Ref.]
9. Poswal FS, Russell G, Mackonochie M, MacLennan E, Adukwu EC, etal. (2019) Herbal Teas and their Health Benefits: A Scoping Review.Plant Foods Hum Nutr 74: 266-276. [Ref.]
10. Da-Costa-Rocha I, Bonnlaender B, Sievers H, Pischel I, Heinrich M(2014) Hibiscus sabdariffa L.-A Phytochemical and PharmacologicalReview. Food Chem 165: 424-443. [Ref.]
11. Piovesana A, Rodrigues E, Norena CPZ (2019) Composition Analysisof Carotenoids and Phenolic Compounds and Antioxidant ActivityFrom Hibiscus Calyces (Hibiscus sabdariffa L.) by HPLC-DAD-MS/MS.Phytochem Anal 30: 208-217. [Ref.]
12. Gamboa-Gómez CI, Rocha-Guzmán NE, Gallegos-Infante JA,Moreno-Jiménez MR, Vázquez-Cabral BD, et al. (2015) Plants WithPotential Use on Obesity and Its Complications. EXCLI J 14: 809-831. [Ref.]
13. Ojulari OV, Lee SG, Nam JO (2019) Beneficial Effects of NaturalBioactive Compounds from Hibiscus sabdariffa L. on Obesity.Molecules 24: 210. [Ref.]
14. Walton RJ, Whitten DL, Hawrelak JA (2016) The efficacy of Hibiscussabdariffa (rosella) in essential hypertension: a systematic review ofclinical trials. Aus J Herbal Med 28: 48-51. [Ref.]
15. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, et al. (2018)PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist andExplanation. Ann Intern Med 169: 467-473. [Ref.]
16. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. (2015)Preferred Reporting Items for Systematic Review and Meta-AnalysisProtocols (PRISMA-P) 2015 Statement. Syst Rev 4: 1. [Ref.]
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al.(1996) Assessing the Quality of Reports of Randomized ClinicalTrials: Is Blinding Necessary? Control Clin Trials 17: 1-12. [Ref.]
18. Hariton E, Locascio JJ (2018) Randomised Controlled Trials - The GoldStandard for Effectiveness Research: Study Design: RandomisedControlled Trials. BJOG 125:1716. [Ref.]
19. Boushehri NS, Karimbeiki R, Ghasempour S, Ghalishourani SS,Pourmasoumi M, et al. (2020) The Efficacy of Sour Tea (Hibiscussabdariffa L.) on Selected Cardiovascular Disease Risk Factors: ASystematic Review and Meta-Analysis of Randomized Clinical Trials.Phytother Res 34: 329-339. [Ref.]
20. Wahabi HA, Alansary LA, Al-Sabban AH, GlasziuoP (2010)The Effectiveness of Hibiscus sabdariffa in the Treatment ofHypertension: A Systematic Review. Phytomedicine 17: 83-86. [Ref.]
21. Aziz Z, Wong SY, Chong NJ (2013) Effects of Hibiscus sabdariffaL. On Serum Lipids: A Systematic Review and Meta-Analysis. JEthnopharmacol 150: 442-450. [Ref.]
22. Hajifaraji M, Matlabi M, Ahmadzadeh-Sani F, Mehrabi Y, Rezaee MS,et al. (2018) Effects of Aqueous Extracts of Dried Calyx of Sour Tea(Hibiscus sabdariffa L.) on Polygenic Dyslipidemia: A RandomizedClinical Trial. Avicenna J Phytomed 8: 24-32. [Ref.]
23. Abubakar SM, Ukeyima MT, Spencer JPE, Lovegrove JA (2019)Acute Effects of Hibiscus sabdariffa Calyces on Postprandial BloodPressure, Vascular Function, Blood Lipids, Biomarkers of InsulinResistance and Inflammation in Humans. Nutrients 11: 341. [Ref.]
24. Mozaffari-Khosravi H, Ahadi Z, Barzegar K (2013) The Effect ofGreen Tea and Sour Tea on Blood Pressure of Patients With Type2 Diabetes: A Randomized Clinical Trial. J Diet Suppl 10: 105-115. [Ref.]
25. McKay DL, Chen CY, Saltzman E, Blumberg JB (2010) HibiscusSabdariffa L. Tea (Tisane) Lowers Blood Pressure in Prehypertensiveand Mildly Hypertensive Adults. J Nutr 140: 298-303. [Ref.]
26. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M,Fatehi F, Noori-Shadkam M (2009) The Effects of Sour Tea (Hibiscussabdariffa) on Hypertension in Patients With Type II Diabetes. J HumHypertens 23: 48-54. [Ref.]
27. Faraji MH, Tarkhani AH (1999) The Effect of Sour Tea (Hibiscussabdariffa) on Essential Hypertension. J Ethnopharmacol 65: 231-236. [Ref.]
28. Mozaffari-Khosravi H, Ahadi Z, Tafti MF (2014) The Effect of Green Teaversus Sour Tea on Insulin Resistance, Lipids Profiles and OxidativeStress in Patients with Type 2 Diabetes Mellitus: A RandomizedClinical Trial. Iran J Med Sci 39: 424-432. [Ref.]
29. Jeenduang N, Sangkaew B, Chantaracha P, Chanchareonsri S,Plyduang T, et al. (2017) APOE and CETP TaqIB PolymorphismsInfluence Metabolic Responses to Hibiscus sabdariffa L. AndGynostemma Pentaphyllum Makino Tea Consumption inHypercholesterolemic Subjects. Asia Pac J Clin Nutr 26: 368-378. [Ref.]
30. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M,Fatehi F (2009) Effects of Sour Tea (Hibiscus sabdariffa) on LipidProfile and Lipoproteins in Patients With Type II Diabetes. J AlternComplement Med 15: 899-903. [Ref.]
31. Perez-Torres I, Torres-Narvaez JC, Guarner-Lans V, Díaz-Díaz E,Perezpeña-Diazconti M, et al. (2019) Myocardial Protection fromIschemia-Reperfusion Damage by the Antioxidant Effect of Hibiscussabdariffa Linnaeus on Metabolic Syndrome Rats. Oxid Med CellLongev 2019: 1724194. [Ref.]
32. Ali BH, Cahlikova L, Opletal L, Karaca T, Manoj P, et al. (2017) Effect ofAqueous Extract and Anthocyanins of Calyces of Hibiscus sabdariffa(Malvaceae) in Rats With Adenine-Induced Chronic Kidney Disease.J Pharm Pharmacol 69: 1219-1229. [Ref.]
33. Si LYN, Ali SAM, Latip J, Fauzi NM, Budin SB, et al. (2017) RoselleIs Cardioprotective in Diet-Induced Obesity Rat Model WithMyocardial Infarction. Life Sci 191: 157-165. [Ref.]
34. Chou ST, Lo HY, Li CC, Cheng LC, Chou PC, et al. (2016) Exploringthe Effect and Mechanism of Hibiscus sabdariffa on Urinary TractInfection and Experimental Renal Inflammation. J Ethnopharmacol194: 617-625. [Ref.]
35. Mahmoud YI (2012) Effect of Extract of Hibiscus on the Ultrastructureof the Testis in Adult Mice. Acta Histochem 114: 342-348. [Ref.]
36. Hopkins AL, Lamm MG, Funk JL, Ritenbaugh C (2013) Hibiscussabdariffa L. In the Treatment of Hypertension and Hyperlipidemia:A Comprehensive Review of Animal and Human Studies. Fitoterapia85: 84-94. [Ref.]
37. Lin HH, Chen JH, Wang CJ (2011) Chemopreventive properties andmolecular mechanisms of the bioactive compounds in Hibiscussabdariffa Linne. Curr Med Chem 18: 1245-1254. [Ref.]
38. Lee YS, Yang WK, Kim HY, Min B, Caturla N, et al. (2018) Metabolaid^®Combination of Lemon Verbena and Hibiscus Flower ExtractPrevents High-Fat Diet-Induced Obesity through AMP-ActivatedProtein Kinase Activation. Nutrients 10: 1204. [Ref.]
39. Ezzat SM, Salama MM, El-Din SHS, Saleh S, El-Lakkany NM, et al.(2016) Metabolic Profile and Hepatoprotective Activity of theAnthocyanin-Rich Extract of Hibiscus sabdariffa calyces. Pharm Biol54: 3172-3181. [Ref.]
40. Boix-Castejon M, Herranz-Lopez M, Gago AP, Olivares-Vicente M ,Caturla N , et al. (2018) Hibiscus and Lemon Verbena PolyphenolsModulate Appetite-Related Biomarkers in Overweight Subjects: ARandomized Controlled Trial. Food Funct 9: 3173-3184. [Ref.]
41. Boix-Castejon M, Herranz-Lopez M, Gago AP, Olivares-Vicente M,Caturla N, et al. (2018) Correction: Hibiscus and Lemon VerbenaPolyphenols Modulate Appetite-Related Biomarkers in OverweightSubjects: A Randomized Controlled Trial. Food Funct 9: 4037. [Ref.]
42. Al-Anbaki M, Nogueira RC, Cavin AL, Al-Hadid M, Al-Ajlouni I, et al.(2019) Treating Uncontrolled Hypertension with Hibiscus sabdariffaWhen Standard Treatment Is Insufficient: Pilot Intervention. J AlternComplement Med 25: 1200-1205. [Ref.]
43. Hadi A, Pourmasoumi M, Kafeshani M, Karimian J, Maracy MR, etal. (2017) The Effect of Green Tea and Sour Tea (Hibiscus sabdariffaL.) Supplementation on Oxidative Stress and Muscle Damage inAthletes. J Diet Suppl 14: 346-357. [Ref.]
44. de Arruda A, Cardoso CAL, Vieira M do C, Arena CA (2016) Safetyassessment of Hibiscus sabdariffa after maternal exposure on malereproductive parameters in rats. Drug Chem Toxicol 39: 22-27. [Ref.]
45. Guardiola S, Mach N (2014) Therapeutic Potential of Hibiscussabdariffa: A Review of the Scientific Evidence. Endocrinol Nutr 61:274-295. [Ref.]
46. Adeyemi DO, Adewole OS (2019) Hibiscus sabdariffa RenewsPancreatic β-cells in Experimental Type 1 Diabetic Model Rats.Morphologie 103: 80-93. [Ref.]
47. Souirti Z, Loukili M, Soudy ID, Rtibi K, Özel A, et al. (2016) HibiscusSabdariffa Increases Hydroxocobalamin Oral Bioavailability andClinical Efficacy in Vitamin B₁₂ Deficiency With NeurologicalSymptoms. Fundam Clin Pharmacol 30: 568-576. [Ref.]
48. Peter EL, Rumisha SF, Mashoto KO, Minzi OM, Mfinanga S (2017)Efficacy of Standardized Extract of Hibiscus sabdariffa L. (Malvaceae)in Improving Iron Status of Adults in Malaria Endemic Area: ARandomized Controlled Trial. J Ethnopharmacol 209: 288-293. [Ref.]
49. Kubuga CK, Hong HG, Song WO (2019) Hibiscus sabdariffa MealImproves Iron Status of Childbearing Age Women and PreventsStunting in Their Toddlers in Northern Ghana. Nutrients 11: 198. [Ref.]
50. Carvajal-Zarrabal O, Barradas-Dermitz DM, Orta-Flores Z, Hayward-Jones PM, Nolasco-Hipólito C, et al. (2012) Hibiscus sabdariffa L.,Roselle Calyx, From Ethnobotany to Pharmacology. J Exp Pharmacol4: 25-39. [Ref.]
51. Frankova A, Malik J, Drabek O, Szakova J, Sperlingova I, et al. (2016) InVitro Digestibility of Aluminum from Hibiscus sabdariffa Hot WateryInfusion and Its Concentration in Urine of Healthy Individuals. BiolTrace Elem Res 174: 267-273. [Ref.]

Download Provisional PDF Here

Article Type: RESEARCH ARTICLE

Citation: Etheridge CJ, Derbyshire EJ (2020) Hibiscus Tea and Health: A Scoping Review of Scientific Evidence. Nutr Food Technol Open Access 6(2): dx.doi.org/10.16966/2470-6086.167

Copyright: © 2020 Etheridge CJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication history: